Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 September 2019

Cathay Industrial Biotech
CHF
207
million
CHF
66
million
Y-mAbs Therapeutics
Harmony Biosciences
CHF
65
million
CHF
38
million
Neurelis
Pacira Pharmaceuticals
CHF
36
million
CHF
32
million
Turning Point Therapeutics
CHF
27
million
SpringWorks Therpeutics